Canopy Growth Corporation has renewed its Canopy Growth EU GMP certification for its Kincardine cultivation facility in Ontario. The renewed certification allows Canopy Growth to continue supplying Canadian-grown cannabis to European medical cannabis markets. Canopy Growth Corporation, also known as “Canopy Growth,” announced the certification renewal today. The company trades under TSX: WEED and Nasdaq: CGC.
The company focuses on improving lives through cannabis and expanding its global operations. The renewed certification comes from the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg. The certification confirms Kincardine’s continued compliance with European Union Good Manufacturing Practice standards. As a result, the facility remains an important part of Canopy Growth’s European supply operations.
With its EU GMP status renewed, Canopy Growth can maintain shipments from Kincardine to medical cannabis markets across Europe. Therefore, the certification supports the company’s ongoing international cannabis strategy.
“This renewal reflects the quality, consistency, and reliability of our cultivation operations at Kincardine and our commitment to supplying high-quality EU GMP flower directly from Canada,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. “As our business in Europe grows, we are continuing to broaden our flower portfolio, including through the introduction of MTL Cannabis genetics and additional strains, to meet the evolving needs of patients across the region.”
Kincardine Supports Canopy Growth’s European Supply Chain
Kincardine serves as an anchor asset within Canopy Growth’s complete EU GMP flower supply chain. The facility connects Canadian cultivation operations with the company’s European distribution network.
Canopy Growth also operates a second EU GMP facility in Sankt Leon-Rot, Germany. Together, these facilities support the company’s ability to move cannabis products into European medical markets.
Kincardine’s part in this integrated supply chain is augmented by the updated EU GMP certification for Canopy Growth. This enables the company to continue serving European patients with Canadian-grown medical cannabis. Canopy Growth continues to expand its flower portfolio for European markets. The company plans to bring in MTL Cannabis genetics and other strains.
These additions aim to address changing patient requirements across the region. Moreover, the expanded portfolio could strengthen Canopy Growth’s position within Europe’s developing medical cannabis market.
The certification renewal also arrives as Canopy Growth reports stronger activity across its international cannabis business. Europe remains an important market within the company’s broader international growth strategy.
European Cannabis Business Shows Continued Momentum
Canopy Growth reported a 10% year-over-year increase in international cannabis net revenue during the first quarter of fiscal 2027.
The increase highlights continued momentum across the company’s international cannabis operations. It also comes as Canopy Growth builds its presence across European medical cannabis markets.
The renewed Canopy Growth EU GMP certification gives Kincardine an important role in supporting this growth. EU GMP compliance remains essential for companies supplying pharmaceutical and medical cannabis products into regulated European markets.
Furthermore, Kincardine’s certification helps maintain a direct supply route from Canada to Europe. The facility therefore remains central to Canopy Growth’s international flower strategy.
Canopy Growth’s European operations combine cultivation, manufacturing, and distribution capabilities. This structure allows the company to support its medical cannabis business across multiple stages.
The company will continue developing its European flower portfolio as market demand evolves. At the same time, its Canadian cultivation capabilities will remain important to that strategy.
Overall, the renewed certification reinforces Kincardine’s position within Canopy Growth’s European medical cannabis operations. It also supports the company’s efforts to expand its international cannabis revenue.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
